Insilico Medicine signed a collaboration with Shanghai’s Qilu Pharmaceutical worth up to $120 million to discover small molecules for cardiometabolic diseases using Insilico’s AI drug‑discovery platform. The pact follows a string of recent collaborations that underscore Insilico’s commercial strategy of AI‑enabled preclinical discovery partnerships. The agreement includes upfront and milestone payments to Insilico and spans target selection through early candidate optimization. Insilico has previously announced deals with Servier and Hygtia; the Qilu collaboration positions the company to broaden its footprint in China while bringing partner capital to de‑risk early discovery. The transaction highlights continued appetite from large regional pharmas to partner with AI startups to shorten discovery timelines and to access novel chemical series for high‑value therapeutic areas.